Conditions: Schizophrenia
Allocation: NON_RANDOMIZED | Intervention model: SINGLE_GROUP
Enrollment: 157
Healthy volunteers: no

Brief summary:
This is a multi-site, open-label fixed-flexible dose long-term study of asenapine in participants with schizophrenia. Participants in this study consist of schizophrenia with residual subtype or receiving high dose/multiple antipsychotic drugs, treatment refractory, or elderly participants with schizophrenia. The treatment period is up to 52 weeks.

Detailed description:

Arms:
arm 1: Asenapine 5 mg twice daily (BID) for the first week of treatment, then either 5 mg or 10 mg BID.

Interventions: intervention 1: Asenapine
Intervention descriptions: intervention 1: 5 mg or 10 mg fast-dissolving sublingual tablets BID for up to 52 weeks

Protocol document: